EpilepsyGTx and Viralgen have announced a partnership to advance production of EPY201, EpilepsyGTx’s lead investigational gene therapy for focal refractory epilepsy. The collaboration will support manufacturing ahead of first‑in‑human clinical trials, using Viralgen’s Aava platform to deliver high‑yield, scalable AAV production.
Focal epilepsy refers to disorders in which seizures originate from a specific region of the brain. When seizures continue despite trials of at least two tolerated and appropriately chosen antiseizure medicines, the condition is considered refractory. Around 10 million people worldwide are affected, including two million across the US, UK and EU.
EPY201 is designed for direct administration into the seizure focus to reduce neuronal hyperexcitability locally while limiting exposure beyond the target region. If successful, the approach could provide a single, minimally invasive option that avoids resection or ablation of brain tissue.
Nicolas Koebel, Chief Executive Officer of EpilepsyGTx, said: “Viralgen’s AAV manufacturing expertise and platform designed to support programmes from early development through to commercial scale will be critical as we prepare to advance EPY201 into clinical development.” He added: “Viralgen’s infrastructure, know‑how, and regulatory track record make it an excellent manufacturing partner as we work to bring our novel gene therapy approach closer to the clinic.”
Jimmy Vanhove, Chief Executive Officer of Viralgen, said: “We are proud to partner with EpilepsyGTx on this important programme.” He added: “Our Aava platform is purpose‑built to scale AAV programmes efficiently, and our manufacturing expertise positions us to help EpilepsyGTx advance EPY201 toward patients with focal refractory epilepsy as rapidly as possible.”
Viralgen’s platform has already supported production of 1,500 AAV batches, offering a reliable and efficient route to scale as EPY201 moves toward clinical evaluation.
